2025 Recap: How 20/20 Onsite Drove Clinical Research Innovation by Transforming Patient Retention, Trial Efficiency, and Sponsor Confidence

The most powerful shift in clinical research this year: Bringing the clinic to the patient is no longer optional; it's essential for patient enrollment and retention. 

2025 proved that sponsors don't have to choose between enrollment speed and data quality. Patients don't have to sacrifice weeks of traveling to trial sites. Research teams don't have to worry whether ocular endpoints will derail timelines. 

At 20/20 Onsite, we showed that point-of-need ophthalmic services change everything. We met patients where they live, work, and learn. We protected critical endpoints in complex protocols. We expanded access to underserved communities while maintaining the rigorous protocol demand. 

Here's how we delivered clinical research innovation in 2025. 

2025 at a Glance: Key Milestones 

Why CNS and Neurology Sponsors Keep Choosing Point-of-Need? 

We crossed 20 CNS and neurology trials this year. Ten of those were launched in the last 10 months alone. 

[Note: We support trials in any therapeutic areas that have ocular endpoints. Have an ocular endpoint? We can help!]

This growth reflects a fundamental shift sponsors are making: ocular endpoints are too critical to leave vulnerable (the FDA mandates as such many times as well). Patient travel creates dropout risk. Site limitations create enrollment delays. Point-of-need clinical research innovation eliminates both problems. 

Our Mobile Vision Clinics deploy to trial sites, community centers, workplaces, and patient homes. Certified teams conduct standardized assessments with validated equipment. Sponsors get consistent data without asking patients to travel hours for a 30-minute exam. 

The numbers show it works. More sponsors are choosing this model because it protects timelines, reduces dropout, and maintains the data integrity their protocols demand. 

Common concerns we address: 

• Will mobile assessments match site quality? 
  • Yes. Our teams follow identical protocols and use the same validated equipment regardless of location. 
• Can you scale quickly for multi-site studies? 
  • Yes. Our fleet reaches patients nationwide. We have never missed a screening timeline. 
• How do you maintain consistency across locations? 
  • Standardized workflows, ongoing certification, and rigorous quality controls ensure uniform data capture everywhere we deploy. 

Protecting ocular endpoints no longer means sacrificing speed or access. 

Expanding Our Fleet: Disruptive Innovation in Clinical Trials at Scale 

Our fleet grew to 16 mobile units this year (and counting), a mix of full clinics, pods, and suites designed for different deployment needs. 

This expansion happened because sponsors need flexibility. Some protocols work best with full mobile clinics at trial sites. Others need rapid deployment to patient neighborhoods. Some require both, depending on enrollment challenges in different regions. 

Each unit is equipped with validated diagnostic tools. Each deployment is staffed by certified technicians who follow standardized protocols. Consistency is not negotiable. Sponsors get uniform data quality whether we're in Boston or San Diego - nationwide! 

The result: We can now support more decentralized and hybrid trial models at scale. 

Technology that enables this: 

• Validated ophthalmic equipment in every unit 
• Standardized assessment protocols across all locations 
• Real-time data capture and transmission to study databases 
• Certified teams trained to identical specifications 

Speed without compromise is possible when infrastructure is built for it. 

Industry Recognition for Patient-Centric Clinical Research Innovation 

We earned a Silver Award in the 2025 TITAN Health Awards for transforming healthcare delivery through patient-centric, point-of-need ophthalmic assessments. 

Recognition matters, but what it represents matters more. The clinical research industry is shifting toward models that prioritize patient convenience without sacrificing data integrity. Sponsors are realizing that access barriers hurt enrollment, retention, and diversity. Patients are demanding trials that fit their lives instead of forcing them to rearrange everything around research visits. 

Point-of-need ophthalmic services solve both problems. Patients get convenience. Sponsors get complete datasets. Research sites get reliable endpoint protection without logistical headaches. 

We design every deployment around patient reality: 

• Meeting them at trial sites when proximity works 
• Bringing mobile units to neighborhoods when it doesn't 
• Ensuring every interaction is clear, efficient, and respectful of their time 
• Removing travel, time off work, and childcare as barriers to participation 

This approach improves enrollment, reduces dropout, and builds the diverse trial populations that regulatory agencies and healthcare providers need. 

Maintaining Safety Excellence as We Scale 

Our operations team received a Safety Excellence Award this year, confirmation that quality and safety remain foundational as we grow. 

Scaling creates risk. More units, more deployments, more protocols—each expansion introduces potential for inconsistency. We counter this by maintaining rigorous standards that don't bend under pressure from growth. 

Every team receives ongoing training. Every unit undergoes regular equipment validation. Every process is built to catch issues before they affect patients or data quality. Awards like this confirm what our partners already see: we don't compromise when timelines are tight. 

Sponsors need confidence that every exam meets the highest standards. Patients need to know they're in capable hands. Safety excellence is how we deliver both, regardless of deployment scale or timeline pressure. 

Practices that protect quality during growth: 

• Standardized training and certification for all clinical staff 
• Regular equipment validation and calibration protocols 
• Documented workflows that prevent variability across locations 
• Proactive issue identification systems that surface problems early 

Growth without quality is just volume. We're building both. 

Building Access Beyond Clinical Research 

We partnered with community organizations to provide 900 free eye exams and 800 free glasses to students this year. 

Vision barriers affect learning, safety, and quality of life. Kids who can't see the board fall behind. Families who can't afford glasses watch their children struggle. We're closing those gaps. 

We brought mobile clinics directly to schools and community centers. Students received comprehensive eye exams and prescription glasses, no cost, no barriers, no appointments their families had to juggle. Kids got clarity in classrooms and beyond. Families got peace of mind. 

This work matters for clinical research, too. Expanding access to underserved communities today builds the diverse, representative trial populations we need tomorrow. Patients who trust our community presence become more likely to participate in research. Families who've experienced quality care in familiar settings become more open to clinical trials when opportunities arise. 

Access to compounds. Care provided today creates relationships that support research tomorrow. 

What 2026 Holds? 

This year proved what's possible when you build around patients instead of asking them to fit rigid systems. Next year, we're going further. 

• Clinical Trial Endpoint Protection, Everywhere: We'll keep scaling point-of-need ophthalmic services, so sponsors can de-risk ocular endpoints and keep timelines on track, no matter where their patients are. 
• Speed Without Compromise: More certified teams. More mobile units. More standardized workflows and validated equipment. You'll never have to choose between quality and speed. 
• Access That Compounds: We'll deepen partnerships that bring care to underserved communities. Expanding access today builds the diverse trials and healthier futures we all need. 

Connect with Us About Your Next Protocol 

If you're planning a trial with ocular endpoints or exploring decentralized deployment options through disruptive innovation in clinical trials, we'd be happy to talk. 

Book a call here to schedule a planning conversation for your next project. 

From all of us at 20/20 Onsite, thank you for being part of this community. Here's to a clear, confident start to the new year.